JP2022523554A5 - - Google Patents
Info
- Publication number
- JP2022523554A5 JP2022523554A5 JP2021552600A JP2021552600A JP2022523554A5 JP 2022523554 A5 JP2022523554 A5 JP 2022523554A5 JP 2021552600 A JP2021552600 A JP 2021552600A JP 2021552600 A JP2021552600 A JP 2021552600A JP 2022523554 A5 JP2022523554 A5 JP 2022523554A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- eso
- tcr
- acid sequence
- constant region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024163997A JP2025000725A (ja) | 2019-03-04 | 2024-09-20 | Ｔ細胞受容体及びその使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962813642P | 2019-03-04 | 2019-03-04 | |
| US62/813,642 | 2019-03-04 | ||
| PCT/IB2020/051808 WO2020178739A1 (en) | 2019-03-04 | 2020-03-03 | T cell receptors and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024163997A Division JP2025000725A (ja) | 2019-03-04 | 2024-09-20 | Ｔ細胞受容体及びその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022523554A JP2022523554A (ja) | 2022-04-25 |
| JP2022523554A5 true JP2022523554A5 (enExample) | 2023-03-13 |
| JP7561133B2 JP7561133B2 (ja) | 2024-10-03 |
Family
ID=72337709
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021552600A Active JP7561133B2 (ja) | 2019-03-04 | 2020-03-03 | Ｔ細胞受容体及びその使用方法 |
| JP2024163997A Pending JP2025000725A (ja) | 2019-03-04 | 2024-09-20 | Ｔ細胞受容体及びその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024163997A Pending JP2025000725A (ja) | 2019-03-04 | 2024-09-20 | Ｔ細胞受容体及びその使用方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12692296B2 (enExample) |
| EP (1) | EP3935174A4 (enExample) |
| JP (2) | JP7561133B2 (enExample) |
| KR (1) | KR20210149050A (enExample) |
| CN (1) | CN113906141B (enExample) |
| AU (1) | AU2020231927A1 (enExample) |
| BR (1) | BR112021017464A2 (enExample) |
| CA (1) | CA3132238A1 (enExample) |
| IL (1) | IL286037A (enExample) |
| MX (1) | MX2021010543A (enExample) |
| SG (1) | SG11202109589VA (enExample) |
| TW (1) | TWI872051B (enExample) |
| WO (1) | WO2020178739A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021010537A (es) | 2019-03-04 | 2021-12-10 | Univ Health Network | Receptores de linfocitos t y metodos de uso de estos. |
| AU2020231927A1 (en) | 2019-03-04 | 2021-09-30 | University Health Network | T cell receptors and methods of use thereof |
| US12522644B2 (en) | 2019-03-04 | 2026-01-13 | University Health Network | T cell receptors and methods of use thereof |
| AU2020231693A1 (en) | 2019-03-04 | 2021-09-30 | University Health Network | T cell receptors and methods of use thereof |
| CA3133945A1 (en) | 2019-03-25 | 2020-10-01 | University Health Network | T cell receptors and methods of use thereof |
| WO2023057931A1 (en) * | 2021-10-06 | 2023-04-13 | University Health Network | Modified immune cells and methods of use thereof |
| KR20260024373A (ko) * | 2023-05-05 | 2026-02-20 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 다중-수용체 자연 살해 세포 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2323632A1 (en) | 1998-03-13 | 1999-09-16 | Epimmune Inc. | Hla-binding peptides and their uses |
| CA2388301C (en) | 1999-10-22 | 2011-01-04 | Aventis Pasteur Limited | Modified gp100 and uses thereof |
| US6506875B1 (en) | 2000-09-26 | 2003-01-14 | Ludwig Institute For Cancer Research | Isolated peptides which bind to HLA-C molecules and uses thereof |
| CA2682093A1 (en) | 2007-03-29 | 2008-10-09 | Technion Research & Development Foundation Ltd. | Antibodies, methods and kits for diagnosing and treating melanoma |
| EP3031916B1 (en) * | 2007-06-11 | 2017-06-07 | Takara Bio Inc. | Method for expression of specific gene |
| WO2010037395A2 (en) | 2008-10-01 | 2010-04-08 | Dako Denmark A/S | Mhc multimers in cancer vaccines and immune monitoring |
| WO2010112962A1 (en) | 2009-04-02 | 2010-10-07 | Vaxon Biotech | Identification, optimization and use of cryptic hla-a24 epitopes for immunotherapy |
| US9314516B2 (en) | 2010-05-04 | 2016-04-19 | Cassian Yee | Conditional superagonist CTL ligands for the promotion of tumor-specific CTL responses |
| ES2635335T3 (es) | 2010-09-20 | 2017-10-03 | Biontech Cell & Gene Therapies Gmbh | Receptores de células T específicos de antígeno y epítopos de células T |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| CN105555756B (zh) * | 2013-06-28 | 2018-12-07 | 奥克兰联合服务有限公司 | 氨基酸缀合物和肽缀合物及缀合方法 |
| KR101503341B1 (ko) | 2014-03-12 | 2015-03-18 | 국립암센터 | 자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법 |
| CA2964785A1 (en) | 2014-11-05 | 2016-05-12 | Board Of Regents, The University Of Texas System | Gene modified immune effector cells and engineered cells for expansion of immune effector cells |
| NL2014935B1 (en) | 2015-06-08 | 2017-02-03 | Applied Immune Tech Ltd | T cell receptor like antibodies having fine specificity. |
| CN106632660B (zh) * | 2015-11-04 | 2021-01-29 | 广东香雪精准医疗技术有限公司 | 识别ny-eso-1抗原短肽的tcr |
| JP6895975B2 (ja) | 2016-01-06 | 2021-06-30 | ヘルス リサーチ インコーポレイテッドＨｅａｌｔｈ Ｒｅｓｅａｒｃｈ， Ｉｎｃ． | 組換えｔ細胞受容体を含む組成物及びライブラリー並びに組換えｔ細胞受容体を使用する方法 |
| JP2019521080A (ja) | 2016-04-27 | 2019-07-25 | ユニバーシティ・ヘルス・ネットワーク | ペプチド−ｈｌａ複合体およびその産生方法 |
| US12522644B2 (en) | 2019-03-04 | 2026-01-13 | University Health Network | T cell receptors and methods of use thereof |
| BR112021017404A2 (pt) | 2019-03-04 | 2022-02-01 | Univ Health Network | Receptores de células t e métodos de uso dos mesmos |
| CA3132434A1 (en) | 2019-03-04 | 2020-09-10 | University Health Network | T cell receptors and methods of use thereof |
| AU2020231693A1 (en) | 2019-03-04 | 2021-09-30 | University Health Network | T cell receptors and methods of use thereof |
| EP3935173A4 (en) | 2019-03-04 | 2023-05-31 | University Health Network | T-CELL RECEPTORS AND METHODS OF USE THEREOF |
| AU2020231927A1 (en) | 2019-03-04 | 2021-09-30 | University Health Network | T cell receptors and methods of use thereof |
| MX2021010537A (es) | 2019-03-04 | 2021-12-10 | Univ Health Network | Receptores de linfocitos t y metodos de uso de estos. |
| CA3133945A1 (en) | 2019-03-25 | 2020-10-01 | University Health Network | T cell receptors and methods of use thereof |
-
2020
- 2020-03-03 AU AU2020231927A patent/AU2020231927A1/en active Pending
- 2020-03-03 EP EP20765783.4A patent/EP3935174A4/en active Pending
- 2020-03-03 CN CN202080028561.6A patent/CN113906141B/zh active Active
- 2020-03-03 SG SG11202109589V patent/SG11202109589VA/en unknown
- 2020-03-03 JP JP2021552600A patent/JP7561133B2/ja active Active
- 2020-03-03 MX MX2021010543A patent/MX2021010543A/es unknown
- 2020-03-03 US US17/436,931 patent/US12692296B2/en active Active
- 2020-03-03 KR KR1020217031570A patent/KR20210149050A/ko active Pending
- 2020-03-03 BR BR112021017464A patent/BR112021017464A2/pt not_active IP Right Cessation
- 2020-03-03 WO PCT/IB2020/051808 patent/WO2020178739A1/en not_active Ceased
- 2020-03-03 CA CA3132238A patent/CA3132238A1/en active Pending
- 2020-03-04 TW TW109107111A patent/TWI872051B/zh active
-
2021
- 2021-09-01 IL IL286037A patent/IL286037A/en unknown
-
2024
- 2024-09-20 JP JP2024163997A patent/JP2025000725A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022523552A5 (enExample) | ||
| JP2022527267A5 (enExample) | ||
| JP2022524993A5 (enExample) | ||
| JP2022524994A5 (enExample) | ||
| JP2022523971A5 (enExample) | ||
| JP2022523553A5 (enExample) | ||
| JP2022524992A5 (enExample) | ||
| Baxevanis et al. | Cancer immunotherapy | |
| JP2022543059A5 (enExample) | ||
| Shilyansky et al. | T-cell receptor usage by melanoma-specific clonal and highly oligoclonal tumor-infiltrating lymphocyte lines. | |
| EP2446897A1 (en) | Anti-KIR combination treatments and methods | |
| Tsang et al. | Phenotypic stability of a cytotoxic T-cell line directed against an immunodominant epitope of human carcinoembryonic antigen. | |
| AU2025203036A1 (en) | NKT-cell subset for in vivo persistence and therapeutic activity and propagation of same | |
| US20170232070A1 (en) | Combination Methods for Immunotherapy | |
| CN108138148A (zh) | T细胞的激活和扩增 | |
| US11951131B2 (en) | Anti-SLAMF7 chimeric antigen receptors | |
| JP2022543060A5 (enExample) | ||
| CN113795583B (zh) | T细胞受体及其使用方法 | |
| JP2022543058A5 (enExample) | ||
| CA3052803A1 (en) | Maximizing t-cell memory and compositions and methods therefor | |
| AU2020231694A1 (en) | T cell receptors and methods of use thereof | |
| JP2020533962A5 (enExample) | ||
| JP2023542528A5 (enExample) | ||
| JP2023521219A5 (enExample) | ||
| Mackensen et al. | Induction of tumor-specific cytotoxic T lymphocytes by immunization with autologous tumor cells and interleukin-2 gene transfected fibroblasts |